Jun 11 |
Wolfe Research starts Akero at outperform, cites MASH drug prospects
|
Jun 11 |
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
|
Jun 8 |
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
|
Jun 5 |
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
|
May 29 |
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
|
May 13 |
Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
|
May 10 |
Akero Therapeutics GAAP EPS of -$0.90 beats by $0.05
|
May 10 |
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 8 |
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
|
Apr 30 |
Akero Therapeutics names Scott Gangloff as CTO
|